TAIYO HOLDINGS CO., LTD. ENGLISH TRANSLATION OF JAPANESE-LANGUAGE DOCUMENT
This is a translation of the original Japanese-language document and is provided for convenience only.
In all cases, the Japanese-language original shall take precedence.
Consolidated Financial
Result Digest
FY2022 Q3
(Fiscal Year Ending March 31, 2022)
February 8, 2022
Any information incorporated in this document is not intended for suggestion of purchase or sale of equity share of the company. All the description and projection are based on the company's own analysis at the time of compilation, and their accuracy is not guaranteed. These data may be revised without prior announcement. The company will neither assume nor compensate any loss of anybody resulting from decision based on information provided here.
Copyright © TAIYO HOLDINGS CO., LTD. All Right Reserved.
Our Reporting Segments
Electronic Materials
Develops, manufactures, purchases and sells chemicals for PWBs and other electronic components
Medical and Pharmaceutical
Develops, manufactures, and sells pharmaceuticals and quasi-drugs
Others
Energy business using natural energy, food business, fine chemicals business including dyes, pigments and other chemicals, and ICT business, etc.
2
Copyright © TAIYO HOLDINGS CO., LTD. All Right Reserved.
FY2022 Q3 Overview
Electronic
Materials
Business
Medical and
Pharmaceutical
Business
Company
- Net sales increased by 36% year on year
- Operating income increased by 50% year on year
Main reasons
- New white dry film-type solder resist, which has been mass-produced since the first quarter, was used for Mini LED displays and sold very well
- Strong semiconductor market resulted in record high sales of PKG Products
- Cumulative net sales decreased by 4% year on year
Main reasons
- Lower sales volume of other infectious disease-related products due to thorough countermeasures against the COVID-19 pandemic
- Lower drug price due to the National Health Insurance (NHI) price revision of Long Listed Products
- Higher sales volume of some products as a result of suspensions to the supply of other companies' generic drugs
- Completed the succession of manufacturing and marketing approval and transfer of distribution for all four products from AstraZeneca K.K.
- Acquired treasury stock (until December 31 of FY2021)
Shares acquired : 211,600 shares
Total acquisition amount : Approximately 711 JPY million
- Revision to the financial forecast for the fiscal year ending March 31, 2022
3
Copyright © TAIYO HOLDINGS CO., LTD. All Right Reserved.
Consolidated Financial Results
Taiyo Holdings expects to exceed the consolidated financial forecasts for the full year of FY2022 disclosed on November 5, 2021.
- Updated the financial forecasts for FY2022 3Q to reflect actual results.
- Maintaining the financial forecasts for FY2022 4Q disclosed on November 5, 2021
Results Summary
Unit : JPY Million
① | ② | ②-① | (②-① ) /① | ③ | ②/③ | ④ | ②/④ | ||
FY2022 | |||||||||
FY2021 | FY2022 | FY2022 | |||||||
(as announced | (as revised | ||||||||
on Nov. 5) | on Feb. 8) | ||||||||
3Q Cumulative | 3Q Cumulative | Full year | Full Year | ||||||
Result | Result | YoY | % | Forecast | % | Forecast | % | ||
Net Sales | 60,460 | 73,622 | 13,162 | 22% | 92,200 | 80% | 93,900 | 78% | |
Operating Income | 10,926 | 14,370 | 3,444 | 32% | 15,900 | 90% | 17,000 | 85% | |
Ordinary Income | 10,816 | 14,637 | 3,821 | 35% | 16,000 | 91% | 17,200 | 85% | |
Net Income | 7,706 | 10,360 | 2,654 | 34% | 11,200 | 93% | 12,100 | 86% | |
Exchange rate of | 105.9 | 111.4 | 5.5 | ※1 | ※2 | ||||
JPY/USD | |||||||||
EBITDA | 16,482 | 20,292 | 3,810 | 23% | 23,700 | 86% | 24,900 | 81% | |
Operating Income | 18% | 20% | 17% | 18% | |||||
Margin | |||||||||
EBITDA | 27% | 28% | 26% | 27% | |||||
Margin | |||||||||
※1 JPY/USD exchange rate : Actual results for FY2022 1st half 110.2 JPY. Estimated value for FY2022 2nd half 108.0 JPY. | 4 | ||||||||
※2 JPY/USD exchange rate : Actual results for FY2022 3Q cumulative 111.4 JPY. Estimated value for FY2022 4Q 108.0 JPY. |
Copyright © TAIYO HOLDINGS CO., LTD. All Right Reserved.
Revised Financial Forecast
Forecast for the FY 2022
Unit : JPY Million
Fiscal Year 2022 Forecast | Fiscal Year 2022 Forecast | ||||||
(as revised on Feb. 8)※1 | (as announced on Nov. 5)※2 | ||||||
Consolidated | Electronic | Medical and | Consolidated | Electronic | Medical and | ||
Materials | Pharmaceutical | Materials | Pharmaceutical | ||||
Net Sales | 93,900 | 67,600 | 22,800 | 92,200 | 64,700 | 23,600 | |
Operating Income | 17,000 | 16,100 | 2,200 | 15,900 | 15,400 | 1,900 | |
EBITDA | 24,900 | 18,200 | 6,900 | 23,700 | 17,400 | 6,500 | |
Operating Income | 18% | 24% | 10% | 17% | 24% | 8% | |
Margin | |||||||
EBITDA | 27% | 27% | 30% | 26% | 27% | 28% | |
Margin | |||||||
※1 JPY/USD exchange rate : Actual results for FY2022 3Q cumulative 111.4 JPY. Estimated value for FY2022 4Q 108.0 JPY.
※2 JPY/USD exchange rate : Actual results for FY2022 1st half 110.2 JPY. Estimated value for FY2022 2nd half 108.0 JPY.
5
Copyright © TAIYO HOLDINGS CO., LTD. All Right Reserved.
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
TAIYO Holdings Co. Ltd. published this content on 08 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 February 2022 03:10:03 UTC.
